DE3247062C2 - - Google Patents

Info

Publication number
DE3247062C2
DE3247062C2 DE3247062A DE3247062A DE3247062C2 DE 3247062 C2 DE3247062 C2 DE 3247062C2 DE 3247062 A DE3247062 A DE 3247062A DE 3247062 A DE3247062 A DE 3247062A DE 3247062 C2 DE3247062 C2 DE 3247062C2
Authority
DE
Germany
Prior art keywords
patients
aluminum
deferoxamine
alzheimer
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3247062A
Other languages
German (de)
English (en)
Other versions
DE3247062A1 (de
Inventor
Donald Raymond Prof. Toronto Ontario Ca Mclachlan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE3247062A1 publication Critical patent/DE3247062A1/de
Application granted granted Critical
Publication of DE3247062C2 publication Critical patent/DE3247062C2/de
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE19823247062 1981-12-21 1982-12-20 Verwendung eines chelatbildners als arzneimittel zur behandlung der alzheimer-krankheit Granted DE3247062A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/332,794 US4419365A (en) 1981-12-21 1981-12-21 Method of treating Alzheimer's disease

Publications (2)

Publication Number Publication Date
DE3247062A1 DE3247062A1 (de) 1983-07-07
DE3247062C2 true DE3247062C2 (enExample) 1993-07-01

Family

ID=54774394

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19823247062 Granted DE3247062A1 (de) 1981-12-21 1982-12-20 Verwendung eines chelatbildners als arzneimittel zur behandlung der alzheimer-krankheit

Country Status (6)

Country Link
US (1) US4419365A (enExample)
JP (1) JPS58121213A (enExample)
BE (1) BE895406A (enExample)
DE (1) DE3247062A1 (enExample)
IT (1) IT1155241B (enExample)
ZA (1) ZA829335B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912118A (en) * 1983-09-23 1990-03-27 National Research Development Corporation Pharmaceutical compositions
USRE34313E (en) * 1983-09-23 1993-07-13 National Research Development Corporation Pharmaceutical compositions
US5177068A (en) * 1984-04-19 1993-01-05 National Research Development Corporation Pharmaceutical compositions
KR870700065A (ko) * 1984-12-19 1987-02-28 아놀드 자일러, 에른스트 알테르 신규한 카본산 에스테르
US5217998A (en) * 1985-07-02 1993-06-08 Biomedical Frontiers, Inc. Composition for the stabilization of deferoxamine to chelate free ions in physiological fluid
EP0214101A3 (de) * 1985-09-03 1989-05-31 Ciba-Geigy Ag Verwendung von Eisen(III)-Chelatoren vom Typ Desferrioxamin B und Desferriferrithiocin zur Behandlung von Malaria
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US4743587A (en) * 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US4698431A (en) * 1985-11-12 1987-10-06 The United States Of America As Represented By The United States Department Of Energy Hydroxypyridonate chelating agents
US5707604A (en) * 1986-11-18 1998-01-13 Access Pharmaceuticals, Inc. Vivo agents comprising metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles
US5672334A (en) * 1991-01-16 1997-09-30 Access Pharmaceuticals, Inc. Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans
MX12394A (es) * 1987-07-23 1993-12-01 Ciba Geigy Ag Procedimiento par la obtencion de carbamatos de polietilenglicol.
US4897388A (en) * 1988-12-20 1990-01-30 Geriatric Research Institute, Inc. Method of treating Alzheimer's disease
US5023784A (en) * 1989-04-06 1991-06-11 Doral Technical Services, Inc. Method for diagnosing serum deficiencies
US5158979A (en) * 1989-04-19 1992-10-27 New York University Method and compositions for treating pneumocystic carini infections
US5268165A (en) * 1990-10-16 1993-12-07 Biomedical Frontiers, Inc. Polymer-deferoxamine-ferric iron adducts for use in magnetic resonance imaging
CA2123211C (en) * 1991-11-12 2008-09-16 Colin L. Masters A method for assaying and treating alzheimer's disease
HU214452B (hu) * 1992-06-01 1998-03-30 BIOGAL Gyógyszergyár Rt. Eljárás nagytisztaságú deferoxamin-B-sók előállítására
GB9211779D0 (en) * 1992-06-03 1992-07-15 Ciba Geigy Ag Amine salts
TW274630B (enExample) * 1994-01-28 1996-04-21 Wako Zunyaku Kogyo Kk
JPH0925234A (ja) * 1995-07-12 1997-01-28 Wakunaga Pharmaceut Co Ltd 脳疾患改善剤
US6106866A (en) * 1995-07-31 2000-08-22 Access Pharmaceuticals, Inc. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
BR9813465A (pt) 1997-12-09 2002-01-22 Biomed Frontiers Inc Polissacarìdeos modificados que exibem reconhecimento biológico alterado
US20030236224A1 (en) * 1997-12-09 2003-12-25 Hedlund Bo E. Modified polysaccharides exhibiting altered biological recognition
US6780852B2 (en) 1997-12-09 2004-08-24 Bo E. Hedlund Modified polysaccharides exhibiting altered biological recognition
US7189703B2 (en) * 1998-01-09 2007-03-13 Intracell, Llc Treatment and diagnosis of alzheimer's disease
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
US20050112543A1 (en) * 1998-03-11 2005-05-26 The General Hospital Corporation Method of screening for drugs useful in treating Alzheimer's disease
US6506740B1 (en) 1998-11-18 2003-01-14 Robert A. Ashley 4-dedimethylaminotetracycline derivatives
US6946453B2 (en) 1998-11-18 2005-09-20 Collagenex Pharmaceuticals, Inc. 4-dedimethylaminotracycline derivatives
DE10222561B4 (de) 2002-05-17 2009-12-10 Dr. Franz Köhler Chemie GmbH Protektive Lösung zur Verhinderung von Ischämieschäden
US7728038B2 (en) * 2004-08-04 2010-06-01 University Of Utah Research Foundation Methods for chelation therapy
PL3300742T3 (pl) 2014-07-11 2021-05-04 Grifols Worldwide Operations Limited Transferryna do stosowania w leczeniu zaburzeń związanych z czynnikiem indukowanym hipoksją (HIF) takich jak niedokrwienie
CN112972490B (zh) * 2021-03-04 2022-02-18 中国人民解放军军事科学院军事医学研究院 透明质酸在用于制备预防或治疗铁死亡相关疾病的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1898E (fr) 1903-04-01 1903-11-07 Louis Galland Concasseur à machoires multiples
DE1123436B (de) 1959-09-25 1962-02-08 Ciba Geigy Verfahren zur Herstellung neuer Wuchsstoffe
FR1315046A (fr) 1960-10-11 1963-01-18 Ciba Geigy Procédé de préparation d'acides trihydroxamiques à longue chaîne et de leurs composés complexes
FR1315047A (fr) 1960-10-11 1963-01-18 Ciba Geigy Procédé de préparation d'acides trihydroxamiques à longue chaîne

Also Published As

Publication number Publication date
IT8249698A0 (it) 1982-12-20
IT1155241B (it) 1987-01-21
BE895406A (fr) 1983-06-20
US4419365A (en) 1983-12-06
DE3247062A1 (de) 1983-07-07
JPS58121213A (ja) 1983-07-19
IT8249698A1 (it) 1984-06-20
JPH0318602B2 (enExample) 1991-03-13
ZA829335B (en) 1983-09-28

Similar Documents

Publication Publication Date Title
DE3247062C2 (enExample)
DE69028542T2 (de) Felbamat zur Behandlung der Lennox-Gastaut syndrome
DE69829112T2 (de) Butyrate Derivate zur Behandlung von Fibromyalgia und chronischem Müdigkeits-Syndrom
DE69004837T2 (de) Verwendung von 5-Methyltetrahydrofolsäure, 5-Formyltetrahydrofolsäure sowie deren pharmazeutisch geeigneten Salzen zur Herstellung von Arzneimitteln mit gesteuerter Freigabe und wirksam in der Therapie organisch mentaler Störungen sowie die entsprechenden Arzneimittel.
DE3780618T2 (de) Verwendung von buspiron zur verbesserung des kurzzeitgedaechtnisses.
DE69129115T2 (de) Neues verfahren zur behandlung von depression
DE2920739A1 (de) Verwendung von 8-eckige klammer auf 4-eckige klammer auf 4-(2-pyrimidinyl)-1piperazinyl eckige klammer zu -butyl eckige klammer zu -8-azaspiro eckige klammer auf 4.5 eckige klammer zu decan-7,9-dion
DE69231955T2 (de) Verwendung von N-(2,6-Dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamid zur Behandlung von Demenz
DE3882135T2 (de) Verwendung von melatonin oder seine derivate zur herstellung von arzneimitteln, die gegen alterskrankheiten wirksam sind.
Franks et al. Effects of amobarbital sodium and dexamphetamine sulfate on the conditioning of the eyeblink response.
DE3850154T2 (de) Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression.
DE69201660T2 (de) Verwendung von Acetyl L-Carnitin zur therapeutischen Behandlung von Coma.
DE69605531T2 (de) Carnitinderivat als Arzneimittel zur Behandlung von Arteriosklerose obliterans
EP0575613B1 (de) Verwendung der aminosäure glycin zur herstellung von arzneimitteln mit antistress-, stressschutz- und nootroper wirkung
EP0345247A2 (de) Verwendung von monosubstituierten selenorganischen Verbindungen zur Herstellung eines Arzneimittels sowie daraus hergestelltes Arzneimittel und Verfahren zu seiner Herstellung
EP0294538B1 (de) Verwendung von Nigerizin zur Herstellung eines Mittels zur Behandlung von Virus-Erkrankungen
DE69331008T2 (de) Verwendung von cotinin zur linderung des tabakentzugssyndrom
DE68909304T2 (de) Aminosäuren für der Behandung neurodegenerativer Störungen.
DE2611976A1 (de) Pharmazeutisches praeparat zur besserung und wiederherstellung bei verminderten bewusstseinszustaenden
DE212018000171U1 (de) Zusammensetzung zur Verwendung in der Prävention oder Behandlung von Autismus-Spektrum-Störungen umfassend ein Salz der Benzoesäure
DE2125427A1 (de) Therapeutisches Mittel
DE69631597T2 (de) Kombination aus einem beta rezeptorblocker und einem opioid
DE4023086A1 (de) Methode zur behandlung von allergischer konjunktivitis
DE3789173T2 (de) Verwendung von Ketamin zur Herstellung von Arzneimitteln zur Prävention oder Linderung der Effekte von Schlaganfall bei einer Person mit erhöhtem Risiko für Schlaganfall.
DE3851669T2 (de) Verwendung von Gepiron für Medikamente zur Milderung panischer Zustände.

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee